OramedORMP.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, Oramed (ORMP.O) trades at a P/E of 0.96x, P/B of 0.53x, P/S of N/A, and a dividend yield of 6.14%.
Longitudinal percentile comparison: P/E sits at the 5th percentile over the trailing 10Y window (vs. 5th percentile over 3Y); P/B sits at the 3rd percentile over the trailing 10Y window (vs. 8th percentile over 3Y); P/S historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data).
Cross-sectional valuation: its P/E ranks at the 1st percentile within its industry and the 1st percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 8.94%, ranking at the 96th percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 1.4 points of each other — a consistent signal from both angles. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Of the 8.94% total shareholder yield, 6.14% is paid out as dividends and roughly 2.80% is implied to come from buybacks — both channels are meaningfully in play. Oramed operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: ORMP · ORMP
Want the full picture on whether Oramed (ORMP.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 0.96 | ||||||
| P/B (MRQ) | 0.53 | ||||||
| P/S (TTM) | N/A | — | — | — | — | — | — |
| Dividend Yield | 6.14% | ||||||
| Buyback + Div Yield | 8.94% |